On June 15, 2004, Medical Devices Panel of the FDA recommended that the Food and Drug Administration U.S. approved vagus nerve stimulation therapy for treating chronic or recurrent depression resistant. I was at the meeting, sitting in the front row and made a presentation to the jury. But a year later, still without a final approval by the Food and Drug Administration (FDA). What is the delay? Sen. Chuck Grassley, Chairman of the Senate Finance Committee unexpectedly decided to review the decision of the FDA to allow this therapy used to treat depression. Vagus nerve stimulation therapy has been approved by the FDA for epilepsy for eight years.
Although this is not a formal investigation, it seems that is an impediment to the immediate issuing of final approval from the FDA. I’m not aware of the scientific and medical credentials of the Senate Finance Committee. However, I have first hand knowledge some of the FDA Medical Device Group members lack familiarity with the FDA’s own regulations and guidelines. If you would like to express its outrage at the continued delay of the final FDA approval, please contact: U.S. Senate Finance Committee 219 Dirksen Senate Office Building Washington, DC 20510-6200 Senator Grassley Staff: (202) 224-4515 Senator Baucus Staff: (202) 224-5315 Senator Chuck Grassley Chairman, Senate Finance Committee, 135 Hart Senate Building Washington, DC 20510-1501 (202) 224-3744 Phone Web Link to the e-mail: Ironically, this anniversary coincides with the publication of a baseline survey $ 20,000,000, sponsored by the National Institute of Mental Health. This is the most comprehensive mental health study conducted by the government.
The study reported that 25% of Americans suffer from a psychiatric disorder in the year preceding the survey, but most do not receive adequate attention. Dr. Thomas Insel, director of National Institute of Mental Health, said that “mental disorders are highly prevalent and chronic.” As expected, the researchers found that the most common disorder was depression. The depression began in early adulthood, 20 and 30, and progressively worse and more difficult to treat. If you suffer from chronic or treatment resistant depression, you do not need a research study of U.S. $ 20 million to say that depression is difficult to treat. Charles Donovan was a patient in the research process from the FDA for vagus nerve stimulation and depression. He stated that the Panel in the consultation meeting on 15 June 2004. After 25 years of chronic depression, vagus nerve stimulation completely cured his chronic depression. The author is very grateful and honored by this extraordinary device. Learn more at their website or read about this life-saving, life altering treatment in his book: Outside the Black Hole: Patient Guide to Vagus nerve stimulation and depression. Cancer research gathered all the information.